TY - JOUR
T1 - Efficacy of Systemic Treatment for Leishmania tropica Cutaneous Leishmaniasis
AU - Solomon, Michal
AU - Greenberger, Shoshana
AU - Milner, Maya
AU - Pavlotzky, Felix
AU - Barzilai, Aviv
AU - Schwartz, Eli
AU - Hadayer, Noa
AU - Baum, Sharon
N1 - Publisher Copyright:
© 2022, Medical Journals/Acta D-V. All rights reserved.
PY - 2022
Y1 - 2022
N2 - The effectiveness of systemic treatment for Leishmania tropica cutaneous leishmaniasis remains unclear. The purpose of the study is to evaluate the efficacy and safety of systemic treatments for L. tropica cutaneous leishmaniasis. This retrospective study was performed in 114 patients. Systemic treatments included liposomal amphotericin B and sodium stibogluconate. All patients underwent systemic treatment for L. tropica cutaneous leishmaniasis. Favourable treatment responses were recorded in 72.5% and 70.2% of the patients in the liposomal amphotericin B and sodium stibogluconate groups, respectively; 25.3% and 46% of those in the liposomal amphotericin B and sodium stibogluconate groups respectively, experienced at least one adverse effect. Lesions in cartilaginous areas were associated with higher treatment failure. Prior topical or systemic treatment increased the chance of future systemic treatment success. Liposomal amphotericin B was associated with a shorter intravenous treatment duration and better safety profile. Thus, liposomal amphotericin B is the treatment of choice for L. tropica cutaneous leishmaniasis.
AB - The effectiveness of systemic treatment for Leishmania tropica cutaneous leishmaniasis remains unclear. The purpose of the study is to evaluate the efficacy and safety of systemic treatments for L. tropica cutaneous leishmaniasis. This retrospective study was performed in 114 patients. Systemic treatments included liposomal amphotericin B and sodium stibogluconate. All patients underwent systemic treatment for L. tropica cutaneous leishmaniasis. Favourable treatment responses were recorded in 72.5% and 70.2% of the patients in the liposomal amphotericin B and sodium stibogluconate groups, respectively; 25.3% and 46% of those in the liposomal amphotericin B and sodium stibogluconate groups respectively, experienced at least one adverse effect. Lesions in cartilaginous areas were associated with higher treatment failure. Prior topical or systemic treatment increased the chance of future systemic treatment success. Liposomal amphotericin B was associated with a shorter intravenous treatment duration and better safety profile. Thus, liposomal amphotericin B is the treatment of choice for L. tropica cutaneous leishmaniasis.
KW - Leishmania tropica
KW - cutaneous leishmaniasis
KW - liposomal amphotericin B (LAmB)
KW - sodium stibogluconate
KW - systemic treatment
UR - http://www.scopus.com/inward/record.url?scp=85130863829&partnerID=8YFLogxK
U2 - 10.2340/actadv.v102.2079
DO - 10.2340/actadv.v102.2079
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 35229163
AN - SCOPUS:85130863829
SN - 0001-5555
VL - 102
JO - Acta Dermato-Venereologica
JF - Acta Dermato-Venereologica
M1 - adv00721
ER -